|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000010596 |
|
Date of registration:
|
01/05/2013 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo
|
|
Scientific title:
|
Randomized crossover trial comparing memantine or amantadine for Parkinson's disease with motor fluctuations in Juntendo - MAP-J |
|
Date of first enrolment:
|
2013/05/01 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012290 |
|
Study type:
|
Interventional |
|
Study design:
|
Cross-over Randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Taku Hatano |
|
Address:
|
2-1-1 Hongo Bunkyo Tokyo 113-8421 Japan
Japan |
|
Telephone:
|
03-3813-3111 |
|
Email:
|
thatano@juntendo.ac.jp |
|
Affiliation:
|
Juntendo University School of Medicine Department of Neurology |
|
|
Name:
|
Nobutaka Hattori |
|
Address:
|
2-1-1 Hongo Bunkyo Tokyo 113-8421 Japan
Japan |
|
Telephone:
|
03-3813-3111 |
|
Email:
|
nhattori@juntendo.ac.jp |
|
Affiliation:
|
Juntendo University School of Medicine Department of Neurology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1)Patient has been administered amantadine or memantine already. 2)Patient dose needs to be changed during the study period cholinesterase inhibitors. 3)Patients scheduled to come into effect during the study period deep brain stimulation surgery(DBS). 4)Women and lactating women might be pregnant, are pregnant. 5)In addition, patients attending physician was deemed inappropriate.
Age minimum:
20years-old
Age maximum:
Not applicable
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Parkinson's disease
|
|
Intervention(s)
|
Memantine preceding arm Titrate the memantine, administered for 3 months. And tapering memantine and amantadine titrate the dose for 3 months.
Amantadine preceding arm Titrate the amantadine, administered for 3 months. And tapering amantadine and memantine titrate the dose for 3 months.
|
|
Primary Outcome(s)
|
|
Improvement of dyskinesias
|
|
Secondary Outcome(s)
|
|
Changes in cognitive function score Changes in REM sleep behavior disorder
|
|
Source(s) of Monetary Support
|
|
none
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|